Exosomal NANOGP8 DNA for Early GBM Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for glioblastoma multiforme (GBM) are more prognostic than diagnostic, and there is a need for accessible and accurate markers to detect GBM in its early stages.
Innovation Solution
The use of NANOGP8, a pseudogene associated with exosomal DNA, as a diagnostic biomarker, where the presence of a 22 bp insertion in the 3' UTR is significantly higher in cancerous cells, allowing for the detection of GBM through minimally invasive techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional biomarkers (O6-methylguanine-DNA methyltransferase methylation, isocitrate dehydrogenase 1 mutations) are used for GBM diagnosis, then prognostic information is obtained, but diagnostic accuracy for early-stage detection is insufficient
Solution Approach 1:
The patent extracts and analyzes specific DNA sequences (NANOGP8 pseudogene with 22 bp insertion) from exosomes isolated from patient samples. By focusing on this specific extracted marker rather than traditional bulk tissue markers, the method achieves both diagnostic and prognostic value in peripheral blood samples
Solution Approach 2:
Exosomes serve as an intermediary carrier that transports NANOGP8 DNA from tumor cells to peripheral blood. This intermediary allows non-invasive detection of tumor-specific markers in accessible body fluids, bridging the gap between tumor tissue analysis and liquid biopsy
2Measurement precision
If invasive tissue biopsy is performed to obtain accurate GBM diagnosis, then diagnostic precision is improved, but patient accessibility and comfort deteriorate
Solution Approach 1:
Exosomes act as intermediary carriers that transport tumor-specific DNA markers to peripheral blood, enabling non-invasive liquid biopsy. This intermediary system allows accurate GBM detection through simple blood draws instead of invasive brain tissue biopsies
Solution Approach 2:
The patent uses exosomal DNA as a molecular copy or surrogate of the actual tumor genome. By analyzing NANOGP8 sequences in exosomes circulating in blood, the method creates an accessible copy of tumor genetic information without requiring direct tissue sampling
Data Source
AI summary
Provided are methods of detecting cancer in a patient that involve analyzing DNA in extracellular vesicles. Detection may involve screening for an insert in a 3′ UTR of NANOGP8 present in extracellular vesicles. A method involves (i) obtaining a biological sample containing extracellular vesicles from the patient; (ii) isolating the vesicles from the biological sample; (iii) detecting an amount of NANOG DNA in the vesicles; (iv) comparing the amount of NANOG DNA in the vesicles with vesicles in a non-cancer cell sample, wherein an increased level of NANOG DNA in the vesicles from the patient as compared to the non-cancer cell sample provides a positive indication of cancer in the patient.